natgillin/translations-raw huggingface dataset:
Patients treated with Gazyvaro and bendamustine lived significantly longer on average without their disease getting worse than patients treated with bendamustine alone (29.2 months versus 13.7 months). 
Bolniki, ki so jih zdravili z zdravilom Gazyvaro in bendamustinom, so v povprečju živeli brez poslabšanja bolezni veliko dlje kot bolniki, ki so jih zdravili samo s bendamustinom (29,2 meseca v primerjavi s 13,7 meseca).
By attaching to CD20 on Blymphocytes, obinutuzumab makes the B-lymphocytes a target for the body's immune (defence) system, which kills the B-lymphocytes. 
Obinutuzumab z vezavo na CD20 na limfocitih B povzroči, da ti postanejo tarča imunskega (obrambnega) sistema, ki jih ubije.
For the remaining 5 cycles, Gazyvaro 1,000 mg is given on day one only. 
V preostalih 5 ciklih je treba samo prvi dan cikla dati 1 000-miligramski odmerek.
Gazyvaro is used together with chlorambucil (another cancer medicine) in patients for whom the cancer medicine fludarabine is not recommended; 
Zdravilo Gazyvaro se uporablja skupaj s klorambucilom (drugim zdravilom za zdravljenje raka) pri bolnikih, za katere fludarabin ni priporočljiv.
In one main study involving 781 patients, those treated with Gazyvaro and chlorambucil lived significantly longer on average without their disease getting worse than patients treated with chlorambucil alone (26.7 months versus 11.1 months). 
V eni glavni študiji, v kateri je sodelovalo 781 bolnikov, so tisti, ki so jih zdravili z zdravilom Gazyvaro in klorambucilom, v povprečju živeli brez poslabšanja bolezni veliko dlje kot bolniki, ki so jih zdravili samo s klorambucilom (26,7 meseca v primerjavi z 11,1 meseca).
In CLL, Gazyvaro has been shown to significantly delay the disease getting worse in previously untreated patients who had other medical conditions and were therefore ineligible for fludarabinebased therapy. 
Zdravilo Gazyvaro je znatno upočasnilo slabšanje KLL pri predhodno nezdravljenih bolnikih, ki so imeli tudi druge bolezni, zaradi katerih niso bili primerni za zdravljenje s fludarabinom.
Similarly, patients treated with Gazyvaro and chlorambucil lived significantly longer on average without their disease getting worse than patients treated with rituximab and chlorambucil (26.7 months versus 15.2 months). 
Podobno so bolniki, ki so jih zdravili z zdravilom Gazyvaro in klorambucilom, živeli brez poslabšanja bolezni veliko dlje kot bolniki, ko so jih zdravili z rituksimabom in klorambucilom (26,7 meseca v primerjavi s 15,2 meseca).
Further doses of 1,000 mg are then given on days 8 and 15 of the first cycle. 
Nato je treba 8. in 15. dan prvega cikla dati naslednja 1 000-miligramska odmerka.
Once the disease has responded to treatment, Gazyvaro is then used on its own for the maintenance treatment of FL. 
Po zdravljenju z bendamustinom se zdravilo Gazyvaro uporablja samostojno kot vzdrževalno zdravljenje folikularnega limfoma.
How does Gazyvaro work? 
Kako zdravilo Gazyvaro deluje?
How is Gazyvaro used? 
Kako se zdravilo Gazyvaro uporablja?
A second dose of 900 mg can be given on the same day, if the patient does not have any reactions. 
Če reakcij ni, lahko bolnik isti dan prejme drugi, 900-miligramski odmerek.
Gazyvaro contains the active substance obinutuzumab. 
Zdravilo Gazyvaro vsebuje zdravilno učinkovino obinutuzumab.
• follicular lymphoma (FL), another type of cancer of B-lymphocytes. 
• s folikularnim limfomom (FL), drugo vrsto raka limfocitov B. Zdravilo Gazyvaro se uporablja v kombinaciji s kemoterapijo (drugim zdravilom za raka) pri bolnikih, ki prej niso bili zdravljeni zaradi napredovalega folikularnega limfoma.
Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Ponedeljek Torek Sreda Četrtek Petek Sobota Nedelja
The median duration of treatment was 9.3 months. 
Mediani čas zdravljenja je bil 9,3 meseca.
December 2023 
januarja 2020 decembra 2023
‡ Includes all preferred terms with the word ‘fracture' in bones. 
‡ Vključuje vse prednostne izraze z besedo "zlom" v kosteh
At the time of the primary analysis there were 1,633 patients randomised. 
V času primarne analize je bilo randomiziranih 1.633 bolnikov.
See results below (Table 2). 
Glejte rezultate spodaj (preglednica 2).
You need to know the names of the medicines you take. 
Poznati morate imena zdravil, ki jih jemljete.
Based on Kaplan-Meier estimates. 
Na podlagi Kaplan-Meierjevih ocen.
Medicinal products which prolong the QT interval 
Zdravila, ki lahko podaljšajo interval QT
Therefore, in the three studies it was recommended that patients be maintained on their study treatments until discontinuation criteria were met as specified below for each study. 
Zato se je v vseh treh študijah priporočalo, da bolniki ohranijo svoje študijsko zdravljenje, dokler ne dosežejo kriterijev za prekinitev, ki so določeni spodaj za vsako študijo.
Groups of medicinal products that can be affected include, but are not limited to: 
Skupine zdravil na katere je možen vpliv, vendar ni omejen, so:
NR = Not Reached. 
ND = ni doseženo.
Date of first authorisation: 21 June 2013 Date of latest renewal: 8 February 2018 
Datum prve odobritve: 21 junij 2013 Datum zadnjega podaljšanja: 8. februar 2018
Xtandi is indicated for: 
Zdravilo Xtandi je indicirano za:
No overall differences in safety or effectiveness were observed between these elderly patients and younger patients. 
Med temi starejšimi bolniki in mlajšimi bolniki v celoti niso opazili razlik glede varnosti in učinkovitosti.
Other possible side effects include: 
Med drugimi možnimi neželenimi učinki so:
Theoretically, induction of these transporters is also possible, and the net effect is presently unknown. 
Indukcija teh prenašalcev v teoriji je tudi možna, vendar celotni učinek trenutno ni znan.
Although there was a limited response in some patients from treatment with enzalutamide after abiraterone, the reason for this finding is currently unknown. 
Čeprav so imeli nekateri bolniki omejen odziv na zdravljenje z enzalutamidom po abirateronu, razlog za to ugotovitev trenutno ni znan.
UGT1A1 may have been induced as well. 
Možna je bila tudi indukcija UGT1A1.
Concomitant use with other medicinal products 
Sočasna uporaba z drugimi zdravili
- If you are pregnant or may become pregnant (see ‘Pregnancy, breast-feeding and fertility') 
če ste noseči ali bi lahko zanosili (glejte "Nosečnost, dojenje in plodnost").
Patients with rare hereditary problems of fructose intolerance should not take this medicinal product. 
Bolniki z redko prirojeno motnjo intolerance za fruktozo ne smejo jemati tega zdravila.
The clinical relevance of this observation remains unknown. 
Klinična pomembnost teh ugotovitev ni znana.
The reduction in plasma concentrations can be substantial, and lead to lost or reduced clinical effect. 
Zmanjšanje koncentracij v plazmi je lahko precejšnje, kar vodi do izgube ali zmanjšanega kliničnega učinka.
Keep a list of them with you to show to your doctor when you are prescribed a new medicine. 
Njihov seznam imejte pri sebi, da ga boste pokazali svojemu zdravniku, ko vam bo predpisal kakšno novo zdravilo.
These medicines may influence the effect of Xtandi, or Xtandi may influence the effect of these medicines. 
Ta zdravila lahko vplivajo na učinek zdravila Xtandi, ali pa lahko zdravilo Xtandi vpliva na učinek teh zdravil.
- This medicine could possibly have an effect on male fertility. 
To zdravilo lahko vpliva na moško plodnost.
Patients with serum creatinine > 177 μmol/L (2 mg/dL) were excluded from clinical trials. 
Bolniki s kreatininom v serumu > 177 µmol/l (2 mg/dl) so bili izključeni iz kliničnih preskušanj.
This includes rare cases of seizure with complications leading to death. 
To vključuje redke primere konvulzij z zapleti, ki so povzročili smrt.
P-gp substrates 
Substrati P-gp
Changes in the reproductive organs in both species were consistent with the pharmacological activity of enzalutamide and reversed or partially resolved after an 8-week recovery period. 
Spremembe reproduktivnih organov obeh živalskih vrst so se skladale s farmakološko aktivnostjo enzalutamida in so izginile ali so se delno popravile po 8-tedenskem obdobju okrevanja.
The other ingredients of the film-coated tablets are: 
Druge sestavine filmsko obloženih tablet so:
There are insufficient data to evaluate potential differences in the pharmacokinetics of enzalutamide in other races. 
Podatki ne zadoščajo za ocenitev možnih razlik v farmakokinetiki enzalutamida pri drugih rasah.
ECOG: Eastern Cooperative Oncology Group; BPI-SF: Brief Pain Inventory-Short Form; PSA: Prostate Specific Antigen 
ECOG: Eastern Cooperative Oncology Group; BPI-SF: skrajšan vprašalnik za opis bolečine; PSA: prostatični specifični antigen
Changes in PSA serum concentration independently do not always predict clinical benefit. 
Neodvisne spremembe koncentracij PSA v serumu vedno ne napovedujejo kliničnih koristi.
Seizures are more likely if you take more than the recommended dose of this medicine, if you take certain other medicines, or if you are at higher than usual risk of seizure. 
Napad krčev je verjetnejši, če vzamete večji odmerek tega zdravila od priporočenega, če jemljete nekatera druga zdravila, ali če imate večje tveganje za napad krčev kot običajno.
Most patients in the controlled clinical trials (> 74%) were Caucasian. 
Večina bolnikov v kontroliranih kliničnih preskušanjih (> 74 %) je bila belcev.
This medicine is not for use in children and adolescents. 
Otroci in mladostniki Zdravilo ni namenjeno za uporabo pri otrocih in mladostnikih.
The risk of heart rhythm problems may be increased when using Xtandi. 
Tveganje za težave srčnega ritma je lahko povečano, ko uporabljate zdravilo Xtandi.
This should be taken into account if Xtandi is prescribed in these patients. 
Omenjeno je potrebno upoštevati pri predpisovanju zdravila Xtandi tem bolnikom.
The European Medicines Agency has waived the obligation to submit the results of studies with enzalutamide in all subsets of the paediatric population in prostate carcinoma (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij z enzalutamidom za vse podskupine pediatrične populacije pri karcinomu prostate (glejte poglavje 4.2 za informacije pri pediatrični populaciji).
Enzalutamide is 97% to 98% bound to plasma proteins, primarily albumin. 
Enzalutamid je 97- do 98-odstotno vezan na beljakovine v plazmi, predvsem na albumin.
Results from this analysis were consistent with those from the interim analysis (Table 3, Figure 4). 
Rezultati analize so bili skladni z rezultati vmesnih analiz (preglednica 3, slika 4).
EU/1/13/846/002 (film-coated tablet 40 mg) EU/1/13/846/003 (film-coated tablet 80 mg) 
EU/1/13/846/002 (filmsko obložene tablete 40 mg) EU/1/13/846/003 (filmsko obložene tablete 80 mg)
Analysis of rPFS utilised centrally-reviewed radiographic assessment of progression. 
Pri analizi rPFS so uporabili centralno pregledane radiografske ocene napredovanja bolezni.
P-value is derived from an unstratified log-rank test. 
Vrednost p je dobljena na podlagi nestratificiranega log-rang testa.
Tell your doctor if you are taking, have recently taken or might take any other medicines. 
Obvestite svojega zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Daily fluctuations in plasma concentrations are low (peak-to-trough ratio of 1.25). 
Dnevna nihanja koncentracije v plazmi so majhna (razmerje med največjo in najmanjšo 1,25).
Use with chemotherapy 
Uporaba s kemoterapijo
Your doctor may decide that you should stop taking Xtandi. 
Zdravnik se bo morda odločil, da morate prenehati jemati zdravilo Xtandi.
In the controlled clinical studies, patients with prior seizure or risk factors for seizure were excluded. 
V vseh kontroliranih kliničnih študijah so bili bolniki s predhodnimi konvulzijami ali dejavniki tveganja izključeni.
Based on pharmacokinetic data from studies in Japanese and Chinese patients with prostate cancer, there were no clinically relevant differences in exposure among the populations. 
Farmakokinetični podatki, zbrani v študijah pri japonskih in kitajskih bolnikih z rakom prostate, ne kažejo klinično pomembnih razlik v izpostavljenosti med populacijami.
Benign Leydig cell tumours are expected based on the pharmacological properties of this antiandrogen drug and not considered relevant to humans. 
Benigni tumorji Leydigovih celic so pričakovani glede na farmakološke lastnosti tega antiandrogenskega zdravila in jih ne ocenjujejo kot pomembne za človeka.
Caution is required in patients with severe renal impairment as enzalutamide has not been studied in this patient population. 
Pri bolnikih s hudo okvaro ledvic je potrebna previdnost, kajti enzalutamid v tej populaciji bolnikov ni raziskan.
Stimulation of tumour cell growth via the androgen receptor requires nuclear localization and DNA binding. 
Stimulacija rasti tumorskih celic prek androgenskih receptorjev zahteva jedrno lokalizacijo in vezavo DNA.
CYP2C8 plays an important role in the elimination of enzalutamide and in the formation of its active metabolite. 
CYP2C8 ima pomembno vlogo pri odstranjevanju enzalutamida in tvorbi njegovega aktivnega presnovka.
All patients continued on a LHRH analogue or had prior bilateral orchiectomy. 
Vsi bolniki so nadaljevali zdravljenje z analogom LHRH ali so imeli predhodno obojestransko orhidektomijo.
This medicine contains less than 1 mmol sodium (less than 23 mg) per film-coated tablet, that is to say essentially ‘sodium-free'. 
To zdravilo vsebuje manj kot 1 mmol natrija (manj kot 23 mg) v eni filmsko obloženi tableti, kar v bistvu pomeni "brez natrija".
If you are allergic to enzalutamide, this may result in a rash or swelling of the face, tongue, lip or throat. 
Če ste alergični na enzalutamid, se vam lahko pojavi izpuščaj ali otekanje obraza, jezika, ustnic ali žrela.
There is also a risk of increased formation of active metabolites. 
Obstaja tudi tveganje za povečan nastanek aktivnih presnovkov.
In consideration of the long half-life of enzalutamide (5.8 days, see section 5.2), effects on enzymes may persist for one month or longer after stopping enzalutamide. 
Glede na dolgi razpolovni čas enzalutamida (5,8 dneva, glejte poglavje 5.2) lahko vplivi na encime trajajo še en mesec ali več po prenehanju uporabe enzalutamida.
No studies to evaluate the effects of enzalutamide on the ability to drive and use machines have been conducted. 
Študij za ovrednotenje vplivov enzalutamida na sposobnost vožnje in upravljanja s stroji niso izvedli.
An updated survival analysis was conducted when 784 deaths were observed. 
Ko je bilo opaženih 784 primerov smrti, je bila narejena posodobljena analiza preživetja.
Other important adverse reactions include fall, cognitive disorder, and neutropenia. 
Drugi pomembni neželeni učinki vključujejo padce, kognitivne motnje in nevtropenijo.
Pharmacotherapeutic group: hormone antagonists and related agents, anti-androgens, ATC code: L02BB04. 
Farmakoterapevtska skupina: hormonski antagonisti in sorodne učinkovine, antiandrogeni, oznaka ATC: L02BB04.
Patients should be advised of the potential risk of experiencing a psychiatric or neurological event while driving or operating machines. 
Bolnike je treba seznaniti z možnim tveganjem za pojav psihiatričnih ali nevroloških učinkov med upravljanjem vozil in strojev.
The safety and efficacy of concomitant use of Xtandi with cytotoxic chemotherapy has not been established. 
Varnost in učinkovitost sočasne uporabe zdravila Xtandi s citotoksično kemoterapijo ni bila dokazana.
If you have a seizure, worsening headache, confusion, blindness or other vision problems, please contact your doctor as soon as possible. 
Če imate napade krčev, poslabšanje glavobola, zmedenost, izgubo vida ali druge težave z vidom, se čim prej posvetujte s svojim zdravnikom.
Treatment with enzalutamide should be initiated and supervised by specialist physicians experienced in the medical treatment of prostate cancer. 
Zdravljenje z enzalutamidom mora začeti in nadzorovati zdravnik specialist, ki ima izkušnje z zdravljenjem raka prostate.
The AUC of pioglitazone increased by 20% while Cmax decreased by 18%. 
AUC pioglitazona se je povečala za 20 %, Cmax pa se je zmanjšala za 18 %.
- Xtandi can be taken with or without food. 
Zdravilo Xtandi lahko vzamete s hrano ali brez nje.
If you are taking a medicine that can cause seizures or that can increase the susceptibility for having seizures (see ‘Other medicines and Xtandi' below) 
Če jemljete zdravila, ki lahko povzročijo napade krčev ali ki lahko povečajo dovzetnost za napade krčev (glejte "Druga zdravila in zdravilo Xtandi", spodaj).
Any heart or blood vessel conditions, including heart rhythm problems (arrhythmia), or are being treated with medicines for these conditions. 
Kakršnakoli srčno-žilna stanja, vključno s težavami srčnega ritma (aritmije), ali se zdravite z zdravili zaradi teh stanj.
Food has no clinically significant effect on the extent of absorption. 
Hrana nima klinično pomembnega vpliva na obseg absorpcije.
Xtandi is a medicine that works by blocking the activity of hormones called androgens (such as testosterone). 
Zdravilo Xtandi deluje tako, da prepreči delovanje hormonov imenovanih androgeni (kot je testosteron).
The half-life of enzalutamide was however doubled in patients with severe hepatic impairment compared with healthy controls (10.4 days compared to 4.7 days), possibly related to an increased tissue distribution. 
Vseeno je bil razpolovni čas enzalutamida pri bolnikih s hudo okvaro jeter v primerjavi z zdravo kontrolo podvojen (10,4 dni v primerjavi z 4,7 dni), kar je lahko povezano s povečano porazdelitvijo v tkivih.
Based on a mass balance study in humans, oral absorption of enzalutamide is estimated to be at least 84.2%. 
Na podlagi študije masne bilance pri ljudeh je bila peroralna absorpcija enzalutamida ocenjena na vsaj 84,2 %.
Enzalutamide is not for use in women. 
Enzalutamid ni namenjen za uporabo pri ženskah.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. 
V razvrstitvah pogostnosti so neželene reakcije navedene po padajoči resnosti.
In addition to the co-primary efficacy endpoints, statistically significant improvements were also demonstrated in the following prospectively defined endpoints. 
Poleg sočasnih primarnih opazovanih dogodkov so bila statistično značilna izboljšanja dokazana tudi za naslednje prospektivno določene opazovane dogodke.
Use of enzalutamide has been associated with seizure (see section 4.8). 
Uporaba enzalutamida je bila povezana s konvulzijami (glejte poglavje 4.8).
The active metabolite is 95% bound to plasma proteins. 
Aktivni presnovek je 95-odstotno vezan na beljakovine v plazmi.
- If you forget to take Xtandi for more than one day, talk to your doctor immediately. 
Če ste zdravilo Xtandi pozabili vzeti več kot en dan, se takoj posvetujte z zdravnikom.
There is no antidote for enzalutamide. 
Antidota za enzalutamid ni.
• Statins metabolised by CYP3A4 (e.g. atorvastatin, simvastatin) 
• statini, ki se presnavljajo s CYP3A4 (npr. atorvastatin, simvastatin)
Interactions with certain medicinal products that are eliminated through metabolism or active transport are expected. 
Medsebojno delovanje z določenimi zdravili, ki se izločajo preko presnove ali z aktivnim prenosom je pričakovano.
Most patients (approximately 71%) in the study were Caucasian; 16% were Asian and 2% were Black. 
Večina bolnikov (približno 71 %) v študiji je bilo belcev, 16 % je bilo azijcev in 2 % je bilo črncev.
Approximately 45% of patients had measurable soft tissue disease at study entry, and 12% of patients had visceral (lung and/or liver) metastases. 
Približno 45 % bolnikov je imelo ob vstopu v študijo izmerljivo bolezen mehkega tkiva in 12 % bolnikov je imelo visceralne (pljuča in/ali jetra) metastaze.
28 soft capsules 
28 mehkih kapsul
Median OS was not reached. 
Mediano skupno preživetje ni bilo doseženo.
When taken at the same time as Xtandi, these medicines may increase the risk of a seizure: 
Jemanje teh zdravil hkrati z zdravilom Xtandi lahko poveča tveganje za napade krčev:
Leydig cell hypertrophy and/or hyperplasia were observed in mice (4 weeks) and dogs (39 weeks). 
Hipertrofijo in/ali hiperplazijo Leydigovih celic so opazili pri miših (4 tedni) in psih (39 tednov).
Very common (may affect more than 1 in 10 people) Tiredness, broken bones, hot flushes, high blood pressure 
Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov) utrujenost, zlomi kosti, vročinski oblivi, visok krvni tlak
Based on a population pharmacokinetic analysis, no dose adjustment is necessary for patients with calculated creatinine clearance (CrCL) values ≥ 30 mL/min (estimated by the Cockcroft and Gault formula). 
Na podlagi populacijske farmakokinetične analize odmerka ni treba prilagoditi bolnikom z izračunano vrednostjo očistka kreatinina (CrCL) ≥ 30 ml/min (ocenjeno s formulo po Cockcroftu in Gaultu).
There were no other important changes in clinical pathology or histopathology in any other organ system, including the liver, in either species. 
Drugih pomembnih sprememb v klinični patologiji ali histopatologiji katerega koli drugega organskega sistema (vključno z jetri) ni bilo ne pri eni ne pri drugi vrsti.
Enzalutamide is a potent enzyme inducer and increases the synthesis of many enzymes and transporters; therefore, interaction with many common medicinal products that are substrates of enzymes or transporters is expected. 
Enzalutamid je močan induktor encimov, ki poveča sintezo mnogih encimov in prenašalcev, zato je možna tudi interakcija s pogostimi zdravili, ki so substrati ali prenašalci encimov.
There are two major metabolites in human plasma: N-desmethyl enzalutamide (active) and a carboxylic acid derivative (inactive). 
V človeški plazmi sta dva glavna presnovka: N-desmetil-enzalutamid (aktiven) in karboksilnokislinski derivat (neaktiven).
A gradual dose reduction of the concomitant medicinal product may be necessary when stopping enzalutamide treatment. 
Postopno zmanjševanje odmerka sočasno uporabljanih zdravil bo morda potrebno po prekinitvi zdravljenja z enzalutamidom.
Co-administration with warfarin and coumarin-like anticoagulants should be avoided. 
Sočasni uporabi z varfarinom ali kumarinskimi antikoagulanti se je treba izogniti.
Consistent MFS results were also observed in all pre-specified patient subgroups including PSADT (< 6 months or ≥ 6 months), demographic region (North America, Europe, rest of world), age (< 75 or ≥ 75), use of a prior bone-targeting agent (yes or no). 
Primerljive rezultate MFS so opažali tudi v vseh vnaprej opredeljenih podskupinah bolnikov, vključno s PSADT (< 6 mesecev ali ≥ 6 mesecev), demografsko regijo (Severna Amerika, Evropa, preostali svet), starostjo (< 75 ali ≥ 75 let) in predhodno uporabo sredstev, usmerjenih na kosti (da ali ne).
Maximum plasma concentrations (Cmax) of enzalutamide in patients are observed 1 to 2 hours after administration. 
Največja koncentracija enzalutamida v plazmi (Cmax) se pri bolnikih pojavi od 1 do 2 uri po uporabi zdravila.
• the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy. 
• zdravljenje odraslih moških z metastatskim KORP, pri katerih je bolezen med zdravljenjem ali po zdravljenju z docetakselom napredovala.
Enzyme induction 
Indukcija encimov
The full induction potential of enzalutamide may not occur until approximately 1 month after the start of treatment, when steady-state plasma concentrations of enzalutamide are reached, although some induction effects may be apparent earlier. 
Polni indukcijski potencial enzalutamida se lahko razvije šele po približno 1 mesecu od začetka zdravljenja, ko je dosežena plazemska koncentracija v stanju dinamičnega ravnovesja; nekateri indukcijski učinki pa so lahko opazni že prej.
What Xtandi is and what it is used for 
Kaj je zdravilo Xtandi in za kaj ga uporabljamo
Contains sorbitol (E420). 
Vsebuje sorbitol (E420).